Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma

Hepatology Research

Volumn 36, Issue 3, 2006, Pages 195-200

  Uenishi, Takahiro ^a,c   Nishiguchi, Shuhei ^b   Tamori, Akihiro ^a   Yamamoto, Takatsugu ^c   Shuto, Taichi ^d   Hirohashi, Kazuhiro ^d   Takemura, Shigekazu ^a   Tanaka, Hiromu ^a   Kubo, Shoji ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c Ishikiriseiki Hospital   (Japan)

^d OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Interferon; Postoperative outcome

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; VIRUS RNA;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INFECTION CONTROL; JAPAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OVERALL SURVIVAL; PERSISTENT VIRUS INFECTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; RNA ANALYSIS; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33750084985     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2006.07.011     Document Type: Article

References (30)

1. Yamasaki S., Hasegawa H., Makuuchi M., Takayama T., Kosuge T., and Shimada K. Choice of treatments for small hepatocellular carcinoma: hepatectomy, embolization or ethanol injection. J Gastroenterol Hepatol 6 (1991) 408-413
2. Kanematsu T., Matsumata T., Shirabe K., et al. A comparative study of hepatic resection and transcatheter arterial embolization for the treatment of primary hepatocellular carcinoma. Cancer 71 (1993) 2181-2186
3. Arii S., Yamaoka Y., Futagawa S., et al. Results of surgical and nonsugical treatment for small-size hepatocellular carcinoma: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32 (2000) 1224-1229
4. Kubo S., Nishiguchi S., Shuto T., et al. Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. Jpn J Cancer Res 90 (1999) 162-170
5. Kubo S., Hirohashi K., Tanaka H., et al. Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. World J Surg 24 (2000) 1559-1565
6. Shirabe K., Takenaka K., Taketomi A., et al. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 77 (1996) 1050-1055
7. Tarao K., Takemiya S., Tamai S., et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 79 (1997) 688-694
8. Sakon M., Umeshita K., Nagano H., et al. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 135 (2000) 1456-1459
9. Kasahara A., Hayashi N., Mochizuki K., et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 27 (1998) 1394-1402
10. Imai Y., Kawata S., Tamura S., et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 129 (1998) 94-99
11. Ikeda K., Saitoh S., Arase Y., et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29 (1999) 1124-1130
12. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of chronic and nonchronic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 (1999) 174-181
13. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 351 (1998) 1535-1539
14. Shiratori Y., Imazeki F., Moriyama M., et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132 (2000) 517-524
15. Nishiguchi S., Kuroki T., Nakatani S., et al. Randomised trial of effects interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346 (1995) 1051-1055
16. Nishiguchi S., Shiomi S., Nakatani S., et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357 (2001) 196-197
17. Kubo S., Nishiguchi S., Hirohashi K., et al. Influence of previous interferon therapy on recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res 92 (2001) 59-66
18. Uenishi T., Kubo S., Hirohashi K., et al. Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 24 (2002) 404-412
19. Kubo S., Nishiguchi S., Hirohashi K., et al. Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: A randomized, controlled trial. Ann Intern Med 134 (2001) 963-967
20. Kubo S., Nishiguchi S., Hirohashi K., et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89 (2002) 418-422
21. Kudo M., Chung H., and Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38 (2003) 207-215
22. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 4th ed. Tokyo: Kanehara; 2000. p. 19 [in Japanese].
23. Kudo M., Chung H., Haji S., et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40 (2004) 1396-1405
24. Edmondson H.A., and Steiner P.E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7 (1954) 462-503
25. Knodell R.G., Ishak K.G., Black W.C., et al. Formation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
26. Desmet V.J., Gerber M., Hoofnagle J.H., et al. Classisfication of chronic hepatitis: diagnosis, grading and staging. Hepatology 19 (1994) 1513-1520
27. Sherlock S. Viruses and hepatocellular carcinoma. Gut 35 (1994) 828-832
28. Ikeda K., Saitoh S., Koida I., et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18 (1993) 47-53
29. Takano S., Yokosuka O., Imazeki F., et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 21 (1995) 650-655
30. Kubo S., Nishiguchi S., Tamori A., et al. Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C. Hepatogastroenterology 47 (2000) 1100-1102